News
With cancer drug in trials, Mersana gets $6M
Fri, 04/22/2011 - 5:37am
Mersana Therapeutics Inc has raised $6 million of a planned $10 million debt round with private investors, the company reported in a regulatory filing on Thursday.
The Cambridge company develops medicines using a proprietary, biodegradable polymer it calls Fleximer.
